Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ
Healthcare
Biotechnology
$5.09
▼ -4.50%
Market Cap
$306.1M
Sector
Healthcare
Industry
Biotechnology
Beta
0.60
52-Wk Range
4.14-9.94
CEO
Mihael H. Polymeropoulos
Country
US
Currency
USD
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disor…
Open full interactive analysis & DCF →